This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® in the long-term treatment of patients with a SGA (small for gestational age) short stature where the growth plate in the long bones (epiphyseal disc) is not closed. An extension to the GHLIQUID-1517 trial (NCT00184717).
Study Type
OBSERVATIONAL
Enrollment
227
Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
Novo Nordisk Investigational Site
Tokyo, Japan
Number and type of suspected serious adverse drug reactions (SADRs) during the study period
Time frame: evaluated binannually for 9 years
Number of glucose intolerance events during the study period
Time frame: evaluated biannually for 9 years
Adult height
Time frame: Fulfilment will be evaluated once a year. Height when closure of ephiphyseal discs exists or when accomplished adult height is confirmed by physician
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.